The pharmaceutical community is buzzing with anticipation surrounding retatrutide, a new dual GIP and GLP-1 agonist that’s showing significant efficacy in clinical trials for managing obesity. Unlike some available weight loss approaches, retatrutide appears to offer a greater substantial reducti